ResearcherUniversity of CologneActive in the last 2 years

Silvia von Karstedt

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0002-7816-5919; OpenAlex author ID A5032621420. Sources: OpenAlex.

Their work

Papers: 3 (first author 1, last author 1)
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 11

Papers, trials and grants by year

2018: 2 papers · 2019: none · 2020: none · 2021: none · 2022: none · 2023: none · 2024: none · 2025: none · 2026: 1 paper

Papers 3

Closest collaborators

The 11 strongest of 11 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Anna Trauzold · 2 shared papers, 2018–2026 · strength 0.29
- Paper Oncogenic KRAS-driven type I interferon signalling primes pancreatic cancer for necroptosis. DOI 10.1038/s41467-026-73189-8 ↗
- Paper Should We Keep Walking along the Trail for Pancreatic Cancer Treatment? Revisiting TNF-Related Apoptosis-Inducing Ligan… DOI 10.3390/cancers10030077 ↗
Alexander Quaas · 1 shared paper, 2026 · strength 0.20
- Paper Oncogenic KRAS-driven type I interferon signalling primes pancreatic cancer for necroptosis. DOI 10.1038/s41467-026-73189-8 ↗
Moritz Reese · 1 shared paper, 2026 · strength 0.20
- Paper Oncogenic KRAS-driven type I interferon signalling primes pancreatic cancer for necroptosis. DOI 10.1038/s41467-026-73189-8 ↗
Sofya Tishina · 1 shared paper, 2026 · strength 0.20
- Paper Oncogenic KRAS-driven type I interferon signalling primes pancreatic cancer for necroptosis. DOI 10.1038/s41467-026-73189-8 ↗
Maximilian Reichert · 1 shared paper, 2026 · strength 0.20
- Paper Oncogenic KRAS-driven type I interferon signalling primes pancreatic cancer for necroptosis. DOI 10.1038/s41467-026-73189-8 ↗
Janine Murr · 1 shared paper, 2026 · strength 0.20
- Paper Oncogenic KRAS-driven type I interferon signalling primes pancreatic cancer for necroptosis. DOI 10.1038/s41467-026-73189-8 ↗
Igor A. Astsaturov · 1 shared paper, 2026 · strength 0.20
- Paper Oncogenic KRAS-driven type I interferon signalling primes pancreatic cancer for necroptosis. DOI 10.1038/s41467-026-73189-8 ↗
Anna-Laura Kretz · 2 shared papers, 2018 · strength 0.18
- Paper Should We Keep Walking along the Trail for Pancreatic Cancer Treatment? Revisiting TNF-Related Apoptosis-Inducing Ligan… DOI 10.3390/cancers10030077 ↗
- Paper The Emerging Role of Cyclin-Dependent Kinases (CDKs) in Pancreatic Ductal Adenocarcinoma. DOI 10.3390/ijms19103219 ↗
Johannes Lemke · 2 shared papers, 2018 · strength 0.18
- Paper Should We Keep Walking along the Trail for Pancreatic Cancer Treatment? Revisiting TNF-Related Apoptosis-Inducing Ligan… DOI 10.3390/cancers10030077 ↗
- Paper The Emerging Role of Cyclin-Dependent Kinases (CDKs) in Pancreatic Ductal Adenocarcinoma. DOI 10.3390/ijms19103219 ↗
Balbina García-Reyes · 1 shared paper, 2018 · strength 0.09
- Paper The Emerging Role of Cyclin-Dependent Kinases (CDKs) in Pancreatic Ductal Adenocarcinoma. DOI 10.3390/ijms19103219 ↗
Jan-Philipp Ruff · 1 shared paper, 2018 · strength 0.09
- Paper The Emerging Role of Cyclin-Dependent Kinases (CDKs) in Pancreatic Ductal Adenocarcinoma. DOI 10.3390/ijms19103219 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.